Mylan

919 articles with Mylan

• 

  Grocer's Union Sues AbbVie Over Humira Patents

  3/21/2019

  The United Food and Commercial Workers Local 1500 (UFCW Local 1500) filed a class action lawsuit against AbbVie for allegedly using a group of patents to maintain a monopoly on its blockbuster Humira (adalimumab).

• SBP, Mylan Present Keys to Hurricane Maria Survivor in Welcome Home Party -- Courtesy of $1M Pledge from the Mylan Charitable Foundation

  3/7/2019

  Money to Aid Ongoing Recovery Efforts in Puerto Rico, Funding the Rebuild and Repair of at Least 100 Homes

• Mylan to Present at Raymond James 40th Annual Institutional Investors Conference

  2/28/2019

  Global pharmaceutical company Mylan N.V. announced that CFO Ken Parks will present at the Raymond James 40th Annual Institutional Investors Conference in Orlando, Fla., on Tuesday, March 5, 2019, at 7:30 a.m. ET.

• Mylan Reports Fourth Quarter and Full Year 2018 Results and Provides 2019 Guidance

  2/26/2019

  Mylan N.V. announced its financial results for the fourth quarter and the year ended December 31, 2018 and provided 2019 guidance.

• Mylan Launches Generic Suboxone® Sublingual Film to Treat Opioid Dependence

  2/22/2019

  Global pharmaceutical company Mylan N.V. announced the U.S. launch of Buprenorphine and Naloxone Sublingual Film, 8 mg/2 mg and 12 mg/3 mg, a generic version of Indivior's Suboxone® Sublingual Film.

• Mylan Launches Wixela™ Inhub™ (fluticasone propionate and salmeterol inhalation powder, USP), the First Generic of ADVAIR DISKUS® (fluticasone propionate and salmeterol inhalation powder), at a List Price 70% Less than the Brand

  2/12/2019

  Unique Pricing of Wixela Inhub Immediately Benefits Patients and Reduces Overall Cost to the U.S. Healthcare System

• Mylan to Release 2018 Fourth Quarter and Full Year Results and 2019 Guidance on Feb. 26, 2019

  2/11/2019

  Global pharmaceutical company Mylan N.V. announced that it will release its fourth quarter and full year 2018 financial results, as well as its 2019 financial guidance, on Tuesday, Feb. 26, after the close of the U.S. financial markets.

• 

  A Deeper Look at Drug Shortages in the U.S.

  2/1/2019

  Recently, in the U.S., there has been a shortage of an anti-anxiety drug, buspirone. The American Society of Health-System Pharmacists (ASHP) lists shortages, and as of Jan. 31, 2019, noted shortages of buspirone tablets manufactured by Accord Healthcare, Mylan and Teva Pharmaceutical.

• Mylan Announces FDA Approval of Wixela™ Inhub™ (fluticasone propionate and salmeterol inhalation powder, USP), First Generic of ADVAIR DISKUS® (fluticasone propionate and salmeterol inhalation powder)

  1/31/2019

  Wixela™ Inhub™ is the first FDA-approved therapeutically equivalent generic of ADVAIR DISKUS® (fluticasone propionate and salmeterol inhalation powder) for certain patients with asthma or chronic obstructive pulmonary disease (COPD)

• 

  Mylan Snags FDA Approval for Its Generic Version of GSK’s Advair

  1/31/2019

  Shares of GlaxoSmithKline took a slight dip Wednesday afternoon after the U.S. Food and Drug Administration approved Mylan NV’s generic version of Advair Diskus, a staple blockbuster drug in the U.K. pharmaceutical company’s pipeline.
• 

  Companies Continue to Develop Treatments for Opioid Addiction

  1/22/2019

  As opioid lawsuits continue to wind through the courts, some drugmakers are focused on developing treatments for opioid addiction.

• Mylan to Present at the 37th Annual J.P. Morgan Healthcare Conference

  12/20/2018

  Mylan N.V. today announced that CEO Heather Bresch will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, Calif., on Tuesday, Jan. 8, 2019, at 11 a.m. PT / 2 p.m. ET.

• Sanofi's Formulation Patents on Multibillion-Dollar Lantus® are Invalidated by U.S. Patent and Trademark Office via IPR, Announces Mylan

  12/13/2018

  Mylan achieves key milestone to provide U.S. diabetes patients with more affordable generic version of Sanofi's Lantus® insulin glargine vials

• 

  At Least 16 Generic Drug Companies and 300 Drugs Target of Price-Fixing Investigation

  12/10/2018

  It apparently began with a 2016 federal lawsuit. At that time, 20 state attorneys general filed a federal lawsuit alleging that six generic drug makers artificially inflated and manipulated prices for an antibiotic and an oral diabetes drug. The goal was to reduce competition.

• Mylan Expands its Voluntary Nationwide Recall of Valsartan Tablets, USP, Amlodipine and Valsartan Tablets, USP, and Valsartan and Hydrochlorothiazide Tablets, USP, to All Lots Within Expiry Due to the Detection of Trace Amounts of NDEA

  12/4/2018

  Mylan N.V. (NASDAQ: MYL) today announced that its U.S. based Mylan Pharmaceuticals business is expanding its consumer-level voluntary nationwide recall to include all lots of Valsartan-containing products within expiry.

• Mylan Expands Gastroenterology Portfolio with Launch of Generic for Prevacid® SoluTab Delayed-Release Orally Disintegrating Tablets

  12/4/2018

  Mylan's Lansoprazole Delayed-Release Orally Disintegrating Tablets are approved to treat certain types of gastrointestinal ulcers

• 

  Teva Issues Recall of Tainted Blood Pressure Medicine, the Latest Global Recall for Valsartan

  11/28/2018

  There has been another recall for blood pressure medications. This time Teva Pharmaceutical has issued a voluntary recall for combination forms of its blood pressure drug Amlodipine due to cancer-causing impurities discovered in the tablets.

• Mylan to Present at Nasdaq's 39th London Investor Conference

  11/26/2018

  Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it will present at Nasdaq's 39th London Investor Conference on Tuesday, Dec. 4, 2018, at 9:45 a.m. GMT/4:45 a.m. ET

• Mylan Statement in Response to FDA Warning Letter Relating to Morgantown Plant

  11/20/2018

  Mylan N.V. today commented on a Warning Letter issued by the U.S. Food and Drug Administration (FDA) on Nov. 9, 2018, relating to its manufacturing facility in Morgantown, West Virginia.

• Mylan Initiates Voluntary Nationwide Recall of 15 Lots of Valsartan Tablets, USP, Amlodipine and Valsartan Tablets, USP, and Valsartan and Hydrochlorothiazide Tablets, USP, Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine)

  11/20/2018

  Mylan N.V. today announced that its U.S. based Mylan Pharmaceuticals business is conducting a voluntary nationwide recall to the consumer level of select lots of Valsartan-containing products, including six lots of Amlodipine and Valsartan Tablets, USP (including the 5mg/160mg, 10mg/160mg, and 10mg/320mg strengths), seven lots of Valsartan Tablets, USP (including 40 mg, 80 mg, 160 mg, and 320 mg strengths), and two lots of Valsartan and Hydrochlorothiazide Tablets, USP 320mg/25mg strength.